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Abstract: People 80 years of age and older constitute 17.8% of all
lung cancer patients in the United States. Because the life expect-
ancies of 80-year-old men and women are 87.3 years and 89.0 years,
respectively, non-small cell lung cancer shortens lives in addition to
causing morbidity. In this retrospective study, all patients with
chemotherapy-naive advanced non-small cell lung cancer 80 years
of age and older treated at the M. D. Anderson Cancer Center with
one or more follow-ups were identified from the database for the
years 1997 to 2004. A cohort of patients younger than 80 years old
was matched based on treatment year, race, histology, and gender in
a 2:1 ratio. Of 13,690 thoracic oncology patients, 496 (3.6%) were
80 years of age and older, of whom 46 met the criteria. In older and
younger patients, respectively, platinum doublets were given in 43%
versus 79% (p  0.0001), the response rate was 41% versus 47%,
the median progression-free survival was 5.55 versus 3.91
months (p  0.216), and the median overall survival was 10.7
versus 9.8 months (p  0.43). Hematologic and nonhematologic
toxicities were similar. Our data indicate that selected patients 80
years of age and older may tolerate and benefit from chemotherapy,
and prospective evaluation of these patients is indicated.
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Lung cancer is the most common cancer in the world andthe leading cause of cancer-related deaths in Western
countries.1 Non-small cell lung cancer (NSCLC) represents
80% to 85% of all lung cancers. Approximately 40% to 50%
of these patients present with incurable metastatic (stage IV)
disease.2 Most of what we know about the treatment of
advanced NSCLC has been learned from studies of patients
largely younger than 70 years old.
Platinum-based chemotherapy has been shown to both
increase overall survival and improve the quality of life in
patients with an adequate performance status (PS).3,4 A recent
study showed that bevacizumab improves survival when
added to paclitaxel/carboplatin in patients with nonsquamous
NSCLC.5 Additionally, second-line agents such as docetaxel
and pemetrexed improve survival and quality of life,6,7 and
erlotinib improves survival when given as a second- or
third-line agent.8
It is uncertain how well older patients respond to these
chemotherapies, and there is concern about the safety of
treating them. It is important to acquire a better understanding
of the impact of chemotherapy on the elderly because 50%
of cases of advanced NSCLC are diagnosed in patients 70
years of age and older (median age is 70 years old).9 Al-
though the percentage of patients 70 years and older in phase
III trials has been 12% to 27%, a number of retrospective
subset analyses of phase III trials have shown a survival
benefit in patients 70 years of age and older.10 A phase III
trial by Lilenbaum et al.11 studying paclitaxel/carboplatin
versus paclitaxel was stratified for patients older than 70
years of age and showed a statistically improved response
rate and time to progression, although it did not show im-
proved overall survival (p 0.289). Based on these data, it is
believed to be appropriate to treat selected patients older than
70 years of age with platinum doublets. A phase II study
showed that vinorelbine plus gemcitabine in chemotherapy-
naive NSCLC patients 80 years of age and older (12 of 20
patients with advanced disease) was tolerated and showed
activity.12
Although there are limited data on the effectiveness and
safety of chemotherapy for patients 70 years of age and older,
there are almost no data for patients 80 years of age and older,
even though they constitute 17.8% of all lung cancer patients
(80–84 years, 10.98%; 85 years, 6.85%) in the United
States, according to the Surveillance Epidemiology and End
Results program reported in 2004 (data from years 1973 to
2002 varying) (According to a conversation with Milt Eisner,
Health Statistician at Cancer Statistics Branch, Surveillance
Research Program, Division of Cancer Control and Popula-
tion Sciences, National Cancer Institute, Bethesda, MD on
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June 16, 2005) and are likely to continue to grow as a fraction
of the NSCLC population.
Moreover, from actuarial tables of the population at
large, the life expectancies of 80-year-old men and women
are 87.3 and 89.0 years, respectively.13 In addition only a
minority of these 80 years of age and older and 85 years of
age and older have dementia.14,15 Advanced NSCLC not only
causes morbidity but may also rob them of many years
meaningful of life. Therefore, it is important to learn whether
there is a role for chemotherapy in these patients. We present
data from a retrospective review of the outcome of all
NSCLC patients 80 years and older who were treated at The
University of Texas M. D. Anderson Cancer Center
(MDACC) between 1997 and 2004 compared with matched
control patients younger than 80 years old.
PATIENTS AND METHODS
The MDACC Surveillance Committee (institutional re-
view board) approved our retrospective review of the pa-
tients’ medical records for this study. A list of all thoracic
oncology patients registered at MDACC between 1997 and
2004 was obtained. The registry includes age, gender, race,
histology, and date of registration. To study these patients, we
identified both a group of patients 80 years of age and older
and a group of matched controls made up of patients younger
than 80 years old. We first identified the patients 80 years of
age and older seen at MDACC between the years of 1997 and
2004, the years covered in the registry. We then identified the
subset of these patients who had advanced (stages IV and III
with malignant effusions) chemotherapy-naive NSCLC
treated at MDACC at least once with systemic therapy with
at least one follow-up. We studied a uniform population so
our results would be more interpretable. Once these patients
were identified, we then formed a control of patients younger
than 80 years old matched by histology, race, gender, and
same year of first chemotherapy with the 80 years of age and
older patients. To do this, the database was placed on an
Excel spreadsheet. Once the patient list was sorted by histol-
ogy, race, and admission date, the database was searched
patient by patient until two matched controls of patients
younger than 80 years old were identified. We then did a
chart review to collect data on PS, weight loss, first-line
chemotherapy regimen, toxicity, dose delay, dose reduction,
date of first chemotherapy, and whether second-line chemo-
therapy was given. We also evaluated whether patients re-
ceived a standard dose of chemotherapy from clinical notes.
Clinical response to first-line chemotherapy was defined as
any decrease in tumor volume based on clinical and radio-
graphic assessments and included both partial remissions and
minor responses (tumor shrinkage  partial remission).
As a separate question, we looked at whether patients
80 years of age and older registered at MNACC had a
different likelihood of being treated here compared with
younger patients. We calculated the percentage of patients
with chemotherapy-naive advanced NSCLC from each age
group (younger than 80 years of age versus 80 years of age
and older) who had received at least one cycle of chemother-
apy and had come to MDACC for at least one follow-up visit.
Because the number of patients younger than 80 years old in
the database was large, we looked at a subset as follows. We
identified another group of patients different from the
younger than 80 years old matched controls mentioned
above. To do this, we again looked at the 13,194 patients
younger than 80 years old in the database. From this, we
randomly selected a subset of 1100 patients from this group
by sorting by registration date and then selecting every 12th
patient from the list. From these 1100 patients, we identified
a subset of patients with advanced NSCLC who were che-
motherapy-naive on presentation and calculated the propor-
tion of these patients who received at least one cycle of
chemotherapy and one follow-up visit at MDACC.
Statistical Analysis
The associations between categorical variables were
assessed via cross tabulation, the 2 test, or the Fisher exact
test as appropriate. Patient characteristics were analyzed for
their associations with time-to-event by using the stratified
Cox proportional hazards progression model, which was used
because of the paired nature of the data set. Overall survival
was defined as the time from the date of the first chemother-
apy to the time of death from any cause. Progression-free
survival was defined as the date of chemotherapy to the date
of progression or death from any cause. Patients alive and
progression free at the date of last follow-up were censored.
Estimates of survival curves were calculated according to the
Kaplan–Meier product-limit method. The distribution of sur-
vival times between patients with different characteristics
was compared by means of the log-rank test. Variables with
p values 0.10 from the univariate Cox proportional hazards
model were included in a multivariate model. All computa-
tions were carried out on a D PC using the Windows NT
operating system in SAS (SAS Institute, Inc., Cary, NC) and
S-plus 2000 (Cambridge, MA) (SAS Institute Inc., SAS/
STAT Users Guide, Version 8).
RESULTS
The likelihood of patients 80 years of age and older
being treated compared with the control cohort of patients
younger than 80 years old is presented here. There were
13,690 lung cancer patients registered in the MDACC data-
base between 1997 and 2004. Among them, 496 patients
(3.6%) were 80 years of age and older at the time of
registration. Of these 496 patients, 140 (28%) had advanced
chemotherapy-naive NSCLC, and of these, 46 of 140 (33%)
were treated and had at least one follow-up at MDACC. From
a cohort of 1100 randomly selected patients younger than 80
years old, 315 (29%) had advanced chemotherapy-naive
NSCLC and 109 of 315 (35%) of patients in the control
group (younger than 80 years old) were treated at MDACC
and had at least one follow-up.
The data assessing outcome by comparing the 80 years
of age and older cohort with the matched controls of patients
younger than 80 years old are presented here. In the control
(younger patients), 87 of 92 (95%) were perfect matches with
the study group (older patients) for the characteristics we
controlled for (Table 1). Of the five patients who did not fully
match, four had received chemotherapy at least 1 year later
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than the matched patients in the older group (minimum,
13.4 months; maximum, 22.4 months). The fifth patient
was a non-Hispanic white who was matched with a His-
panic patient.
The older and younger groups were then further char-
acterized. The median ages of the older and younger groups
were 82 years (range, 80–88) and 65 years (range, 28–79),
respectively. PS was 0 or 1 in 62.8% and 81.6% of patients in
the older and younger groups, respectively. (p  0.02).
Weight loss in the previous 6 months was comparable for
both groups (p  0.09) (Table 2).
Older patients received platinum doublets less fre-
quently than younger patients (43% versus 79%, p 0.0001).
Sixteen (35%), seven (15%), and three (7%) patients in the
older group received a single-agent chemotherapy (vinorel-
bine, gemcitabine, or docetaxel), gefitinib only, or a nonplati-
num doublet treatment as a first-line chemotherapy, respec-
tively. In contrast, in younger group, six (7%), eight (9%),
and five (5%) patients received single-agent chemotherapy
(gemcitabine, mitomycin, vinorelbine, paclitaxel, or do-
cetaxel), gefitinib only, or a nonplatinum doublet as a first-
line chemotherapy, respectively. Standard doses of chemo-
therapy were given to almost all patients in the older and
younger groups (93.4% versus 94.5%) (p  1.00). The
median number of cycles of first-line chemotherapy for older
and younger patients was four (range, 1–27) and three (range,
1–14) cycles, respectively. Dose reduction was not signifi-
cantly different between the older and younger groups
(21.7% versus 14.1%, p  0.26). Chemotherapy was delayed
due to toxicity at least once in nine (19.6%) and 18 (19.5%)
patients in the older and younger groups, respectively (p 
1.00). The rate of use of at least one granulocyte colony-
stimulating factor treatment was 8.7% in the older and 6.5%
in the younger group (p  0.73). A clinical response was
observed in 19 (41%) patients in the older group and 43
(47%) patients in the younger group. Although there were no
radiographic reports for one patient in each group, clinical
notes were taken into consideration for response evaluation.
The rate of second-line chemotherapy was also similar for
both older and younger patients (41.3% versus 44.6%, p 
0.72) (Table 3).
Hematologic and nonhematologic toxicities were not
significantly different between older and younger patients
(Table 4). Grade 3/4 hematologic toxicity was documented in
six (13%) and 16 (17.4%) patients in the older and younger
groups, respectively (p  0.63). Grade 3/4 nonhematologic
toxicity was documented in seven (15.2%) and 23 (25%)
patients in the older and younger groups, respectively (p 
0.27). These observations held up when controlling for plat-
inum-based chemotherapy (hematologic toxicity, p  0.29;
nonhematologic toxicity, p  0.38) (Table 4).
Fourteen (30%) patients in the older group and 25
(27%) patients in the younger group completed six cycles of
first-line chemotherapy. Nine (20%) patients in the older
group and 14 (15%) patients in the younger group elected to
stop before six cycles because of toxicity (p  0.68). In the
older group, these toxicities were neuropathy (two patients,
one with grade 2 and the other with grade 3), fatigue (four
patients with grade 3), and neutropenia with or without
infection (three patients with grade 4). In the younger group,
the reasons for stopping first-line chemotherapy early because
of toxicity were neutropenic fever (three patients), grade 4
neutropenia (two patients), nausea and vomiting (one with
grade 2 and the other with grade 3), peripheral neurotoxicity
(three patients with grade 3), and other toxicities (four pa-
tients). Two (4.3%) older patients died after the administra-
TABLE 1. Patient Clinical Characteristics Grouped by Age
No. (%) of Patients
Any Systemic Therapy Platinum Doublet
Age <80
(n  92)
Age >80
(n  46)
Age <80
(n  73)
Age >80
(n  20)
Gender
Female 46 (50) 23 (50) 37 (50.6) 10 (50)
p 1.00 1.00
Race
African American 4 (4.3) 2 (4.3) 3 (4) 0 (0)
Hispanic 3 (3.2) 2 (4.3) 2 (2.7) 0 (0)
White 85 (92.3) 42 (91.3) 68 (93) 20 (100)
p 0.95 1.00
Pathology
Adenocarcinoma 38 (41.3) 19 (41.3) 32 (43.8) 9 (45)
BAC 12 (13) 6 (13) 8 (10.9) 3 (15)
Squamous 14 (15.2) 7 (15.2) 13 (17.8) 2 (10)
LCUD 28 (30.4) 14 (30.4) 20 (27.3) 6 (30)
p 1.00 0.86
BAC, bronchioloalveolar carcinoma; LCUD, large cell undifferentiated.
TABLE 2. Patient Performance Status and Weight Loss
Grouped by Age
No. (%) of Patients
Any Systemic Therapy Platinum Doublet
Age <80
(n  92)
Age >80
(n  46)
Age <80
(n  73)
Age >80
(n  20)
PS
0 or 1 71 (77.2) 27 (58.7) 60 (82.2) 17 (85)
2 or 3 16 (17.4) 16 (34.8) 9 (12.3) 2 (10)
NA 5 (5.4) 3 (6.5) 4 (5.5) 1 (5)
p 0.02 1.00
Weight loss
5% 64 (69.6) 31 (67.4) 54 (74) 16 (80)
5–10% 12 (13) 9 (19.6) 7 (9.6) 4 (20)
10% 16 (17.4) 2 (4.3) 12 (16.4) 0 (0)
NA 0 (0) 4 (8.7) 0 (0) 0 (0)
p 0.09 0.07
Smoking history
Never smoked 15 (16.7) 11 (24.4)
Ever smoked 75 (83.3) 34 (75.6)
p 0.35
PS, performance status; NA, not available.
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tion of the first cycle of chemotherapy; one died of neutro-
penic sepsis and the other died of unknown causes. Two
(2.1%) younger patients died after the first chemotherapy
cycle. One died of ischemic bowel perforation, and a second
younger patient died of an unknown cause.
Events (tumor progression or death from any cause)
were noted in 45 of 46 (98%) older patients and 88 of 92
(96%) younger patients. The median progression-free sur-
vival for older and younger patients were 5.55 (95% confi-
dence interval [CI]: 3.88–8.02) and 3.91 (95% CI: 3.35–
5.45) months (p  0.216), respectively (Figure 1). In the
univariate analysis, older patients tended to have better pro-
gression-free survival than younger patients (hazard ratio 
0.63 [95% CI: 0.39–1.02]; p  0.06).
As of this writing, 37 of 46 (80%) and 75 of 92 (82%)
deaths have occurred in the older and younger patient groups,
respectively. The median overall survival was 10.7 (95% CI:
6.87–18.2) months for the older patients and 9.8 (95% CI:
7.72–13.4) months for the younger patients (Figure 2) (p 
0.43). Overall survivals of the older and younger patients
according to the PS and whether they received platinum-
based chemotherapy are summarized in Table 5. Survival
analyses by the multivariate Cox proportional hazard model
were done controlling for PS, weight loss, and smoking
status. Weight loss of 5% predicted worse survival in
patients 80 (HR  3.11, p  0.02) but did not reach
significance in patients younger than 80 years old (HR 
1.35, p  0.27). Poor PS did not reach statistical significance
for worse survival in patients 80 years and older (HR 
1.78, p  0.18), but did in patients younger than 80 years old
(HR  2.13, p  0.01). Ever smoking did not significantly
affect survival in patients 80 years and older (HR  0.720,
FIGURE 1. Kaplan–Meier estimates of progression-free sur-
vival grouped by age. E, events; N, total number of patients.
FIGURE 2. Kaplan–Meier estimates of overall survival
grouped by age. E, events; N, total number of patients.
TABLE 3. Patient Treatment Characteristics Grouped
by Age
No. (%) of Patients
Any Systemic Therapy Platinum Doublet
Age <80
(n  92)
Age >80
(n  46)
Age <80
(n  73)
Age >80
(n  20)
Dose reduction
Yes 13 (14.1) 10 (21.7) 12 (16) 5 (25)
p 0.26 0.51
Chemotherapy cycle delay
Yes 18 (19.5) 9 (19.6) 17 (23) 4 (20)
p 1.00 1.00
Standard dose
Yes 87 (94.5) 43 (93.4) 70 (96) 18 (90)
p 1.00 0.29
G-CSF use
Yes 6 (6.5) 4 (8.7) 5 (7) 2 (10)
p 0.73 0.64
Second-line chemotherapy
Yes 41 (44.6) 19 (41.3) 35 (48) 12 (60)
p 0.72 0.45
G-CSF, granulocyte colony-stimulating factor.
TABLE 4. Patient Toxicity Profiles Grouped by Age
No. (%) of Patients
Any Systemic Therapy Platinum Doublet
Age <80
(n  92)
Age >80
(n  46)
Age <80
(n  73)
Age >80
(n  20)
Grade 3/4 hematologic toxicity
Yes 16 (17.4) 6 (13) 12 (16.4) 1 (5)
p 0.63 0.29
Grade 3/4 nonhematologic toxicity
Yes 23 (25) 7 (15.2) 20 (27.4) 3 (15)
p 0.27 0.38
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p  0.50) or in patients younger than 80 years old (HR 
1.55, p  0.24).
DISCUSSION
We report outcomes of a substantial number of patients
with advanced stage NSCLC 80 years of age and older who
were treated with chemotherapy. Our results showed that
selected patients with advanced NSCLC 80 years and older
can tolerate and respond to standard chemotherapy. We also
observed that there were similar outcomes in older and
younger patients in most of the subsets examined. Moreover,
this similarity between the older and younger patients was
observed whether patients received platinum-based combination
chemotherapy or other chemotherapy. In the case of overall
survival, a multivariate analysis controlling for PS, weight loss,
and smoking status demonstrated no statistically significant
difference. The hematologic and nonhematologic toxicities,
number of cycles given, and rate of second-line chemotherapy
were similar between the older and younger groups.
First- and second-line chemotherapy have been estab-
lished as offering survival and quality-of-life benefits to
younger patients with advanced NSCLC with an adequate
PS.3,6,7 Because patients 80 years of age and older constitute
17.8% of all lung cancer patients and the median survival of
healthy octogenarians is approaching a decade, it is important
to consider whether these patients can benefit from chemo-
therapy. However, there are almost no published data to guide
us because very few patients 80 years of age and older are
included in phase III trials. Because elderly patients are often
believed to be unable to tolerate chemotherapy, they are
generally excluded from clinical trials and are typically not
considered appropriate for aggressive platinum-based chemo-
therapy in clinical practice,16 as revealed in a recent analysis
of clinical data from the Southwest Oncology Group.17 How-
ever, an abstract presented in 2005 at the American Society of
Clinical Oncology by Hesketh et al.18 reported outcomes
from two first-line advanced NSCLC trials for patients 70
years of age and older: the Southwest Oncology Group
(S0027) (sequential vinorelbine and docetaxel) and an inves-
tigator-initiated multicenter trial (LUN 6) (single agent do-
cetaxel). Between these trials, the 47 patients (21.5%) who
were 80 years of age and older had similar disease control,
although the patients with a PS of 0/1 had shorter survival
than the younger patients but the very elderly patients with a
PS of 2 had a similar overall survival. They noted that the
regimens were well tolerated by the patients 80 years of age
and older and concluded that selected patients in this age
group may benefit from single-agent chemotherapy. In addi-
tion, there are recent reports indicating a survival benefit in
patients older than 70 years old.10,19 These data encourage us
to investigate whether patients 80 years of age and older
might benefit from standard chemotherapy doublets. How-
ever, there are substantial concerns about treating older pa-
tients. Elderly patients often present with medical and phys-
iologic characteristics20,21 that make the selection of their
optimal treatment more challenging. Moreover, aging causes
physiologic changes in functional status, organ function, and
drug pharmacokinetics. Furthermore, concomitant diseases,
which may significantly affect functional status, general
health, and tumor symptoms, are frequently present in this
patient population.22 These comorbidities may also result in a
higher prevalence of polypharmacy and related risks.23 Given
these health concerns, it is important to carefully assess the
potential benefit.
Our results are encouraging. However, they are only
preliminary. This was a retrospective study, so there may be
selection bias. Thus, patients 80 years of age and older may
have a lesser or greater tendency to be treated, resulting in a
population of patients who are in a different condition than
the younger patients. However, the national Surveillance
Epidemiology and End Results program database has given
the percentage of lung cancer patients 80 years of age and
older as 17.8%, but our data registry showed that these
patients constituted only 3.6% of the MDACC lung cancer
population. This difference suggests that MDACC’s elderly
population may be highly selected and not representative of
the elderly population in the community. However, this
concern is somewhat minimized by the observation that we
treated patients 80 years of age and older at the same rates as
those younger patients once registered at MDACC, although
fewer patients 80 years of age and older were treated with
platinum doublets. Patients 80 years of age and older with a
poor PS who were treated with nonplatinum doublets had
statistically superior survival than younger patients treated
with nonplatinum doublets. Whether this observation is an
accident of the multiple comparisons done, the small numbers
of patients in this subgroup or resulting from underestimating
the performance status in patients 80 years or older as
summarized below is unclear.
To further assess this, we did subset analyses control-
ling for PS and platinum-doublet administration. Interest-
ingly, there was a more exaggerated difference in these
subsets than seen in the populations of older versus younger
patients overall. It is possible that patients 80 years of age and
older who actually have a PS of 1 are often assumed by virtue
TABLE 5. Overall Survival by Factors
Patient
Population Variable Level No.
Median
(mo)
Rate at
1 yr (%) p
All patients Overall 138 10.4 42 0.43
Age 80 92 9.8 40
80 46 10.7 47
PS 0/1 Age 80 71 11.3 45 0.414
80 27 15.0 58
PS 2/3 Age 80 16 4.8 22 0.577
80 16 8.9 25
PS 0/1 with no Age 80 11 9.5 36 0.672
platinum 80 10 13.9 60
PS 0/1 with Age 80 60 11.3 47 0.391
platinum 80 17 18.5 56
PS 2/3 with no Age 80 7 3.2 14 0.033
platinum 80 14 9.5 29
PS 2/3 with Age 80 9 10.9 27 0.196
platinum 80 2 7.0 NA
PS, performance status; NA, not applicable.
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of their age to have a PS of 2. Because the prognosis of
those who migrated, although worse than that for other
members of the PS 0/1 group could be better than those who
actually have a PS of 2/3 in the poor PS group, survival rates
would increase in each group. This would only be true if the
patients 80 years of age and older who had a PS of 1 who
were misassigned actually had on average a worse PS of 1
than the patients with a PS of 1 who were correctly assigned
to the PS 0/1 group. Indeed, this possibility is also supported
by the fact that a larger percentage of patients 80 years of age
and older were assigned a PS of 2. Alternatively, in older
patients, there may be a greater likelihood of noncancer
causes of a poor PS that do not confer as poor a prognosis as
cancer-induced poor PS. Whether either or both of these are
true requires further study. However, it does draw attention to
the concern that we are perceiving elderly patients as being
less able to tolerate therapy than they actually are.
There may be other types of bias as well. Thus as a
retrospective study, information on toxicity and dosing is not
as detailed and reliable as would be the case for patients
treated in a clinical trial. This limits our ability to draw firm
conclusions regarding regimen tolerability because there may
be under- or overreporting of toxicity. In addition, because
our information on dosing was derived from the clinic notes
that reliably indicated the type of chemotherapy and schedule
but typically did not include the doses, it is possible that some
of the doses may have been lower in some of the patients
older than 80 years of age. On that basis, it therefore may
have been more tolerable in the older population. In addition,
some data indicate that older patients tend to have more
indolent tumors, which, if so, would confound the ability to
determine the survival benefit from chemotherapy.24 How-
ever, the similar response rates observed in the older and
younger groups of our study suggest that many of the older
patients did apparently benefit from the chemotherapy.
In summary, our data showed that selected patients 80
years of age and older may tolerate and apparently benefit
from commonly used chemotherapy regimens, including plat-
inum doublets. A patient’s physiologic age rather than chro-
nologic age may be the critical determinant of which type of
chemotherapy to choose. However, determining a patient’s
physiologic age is challenging because we often assume the
physiologic age is older than it is due to age bias. Although
our analysis was retrospective, our results are consistent with
those of other retrospective studies of elderly patients
younger than 70 years old. We believe that our results are
compelling enough to merit a prospective study of patients 80
years of age and older. This will help us determine whether
this large and growing subset of NSCLC patients might
benefit from our most effective regimens. In addition, to
speed up the assessment of whether patients 80 years of age
and older benefit from standard chemotherapy as well as
novel agents, increased efforts to include representative num-
bers of these patients in clinical trials needs to be considered.
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